Stockreport

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data [Yahoo! Finance]

Moleculin Biotech, Inc.  (MBRX) 
Last moleculin biotech, inc. earnings: 8/16 05:35 pm Check Earnings Report
US:NASDAQ Investor Relations: moleculin.com/investors
PDF Full MB-106 trial reaches 20 subjects with CRc of 45% in 1st – 7th line, with median durability at 4.9 months and climbing Interim data supports advancement to develo [Read more]